GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hikma Pharmaceuticals PLC (OTCPK:HKMPY) » Definitions » Cash Ratio

HKMPY (Hikma Pharmaceuticals) Cash Ratio : 0.17 (As of Dec. 2023)


View and export this data going back to 2009. Start your Free Trial

What is Hikma Pharmaceuticals Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Hikma Pharmaceuticals's Cash Ratio for the quarter that ended in Dec. 2023 was 0.17.

Hikma Pharmaceuticals has a Cash Ratio of 0.17. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.

The historical rank and industry rank for Hikma Pharmaceuticals's Cash Ratio or its related term are showing as below:

HKMPY' s Cash Ratio Range Over the Past 10 Years
Min: 0.17   Med: 0.33   Max: 0.97
Current: 0.17

During the past 13 years, Hikma Pharmaceuticals's highest Cash Ratio was 0.97. The lowest was 0.17. And the median was 0.33.

HKMPY's Cash Ratio is ranked worse than
76.59% of 1004 companies
in the Drug Manufacturers industry
Industry Median: 0.585 vs HKMPY: 0.17

Hikma Pharmaceuticals Cash Ratio Historical Data

The historical data trend for Hikma Pharmaceuticals's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hikma Pharmaceuticals Cash Ratio Chart

Hikma Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.32 0.34 0.44 0.27 0.17

Hikma Pharmaceuticals Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Cash Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.44 0.39 0.27 0.24 0.17

Competitive Comparison of Hikma Pharmaceuticals's Cash Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Hikma Pharmaceuticals's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hikma Pharmaceuticals's Cash Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hikma Pharmaceuticals's Cash Ratio distribution charts can be found below:

* The bar in red indicates where Hikma Pharmaceuticals's Cash Ratio falls into.



Hikma Pharmaceuticals Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

Hikma Pharmaceuticals's Cash Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Hikma Pharmaceuticals's Cash Ratio for the quarter that ended in Dec. 2023 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hikma Pharmaceuticals  (OTCPK:HKMPY) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


Hikma Pharmaceuticals Cash Ratio Related Terms

Thank you for viewing the detailed overview of Hikma Pharmaceuticals's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Hikma Pharmaceuticals Business Description

Traded in Other Exchanges
Address
1 New Burlington Place, London, GBR, W1S 2HR
Hikma Pharmaceuticals PLC is engaged in developing, manufacturing, and marketing a broad range of generic, branded and non-branded, in-licensed pharmaceutical products. The firm operates in three segments: injectables, generics, and branded. The majority of the revenue for the company is generated from its injectables segment under which it supplies hospitals across markets with generic injectable products, supported by its manufacturing facilities. Geographically, North America is the company's key revenue generating market followed by Middle East and North Africa, United Kingdom, Europe and the rest of the world.